Kornimate/medical-research-clean huggingface dataset:
acute fetal response to prenatal yoga

Conditions: Pregnancy

Summary: prenatal yoga has become a popular means of exercise during pregnancy.

in 2012, yoga was reported to be practiced by approximately 20 million americans, out of which 82% are women practitioners. the effects of yoga on the fetus have not been demonstrated. the purpose of this study is to evaluate the acute fetal response to yoga exercises by assessing fetal well-being via ultrasound and non-stress testing among healthy women. the investigators hypothesize that yoga during pregnancy does not have any acute negative effects on fetal behavior as assessed by umbilical artery dopplers and fetal heart rate or maternal vital signs.

Eligibility criteria:
inclusion criteria: * uncomplicated singletons pregnancies * gestational age between 28 0/7 and 36 6/7 weeks * no known fetal anomalies * women with no prior experience with yoga * currently receiving routine prenatal care * no contraindications to exercise * able to read and understand english * well dated pregnancy exclusion criteria: * pregnant minors less than 18 years of age * multiple gestations * those patients that have been advised by their doctor not to exercise during this pregnancy (i.e. vaginal bleeding, history of preterm delivery less than 34 weeks, cervical insufficiency, cerclage in place, placenta previa, any chronic medical conditions) * congenital fetal anomalies or intrauterine growth restriction * cigarette smokers * chronic narcotic dependence

Keywords: prenatal yoga yoga, pregnancy yoga, fetal response
limbal stem cell deficiency of genetic origin: genotype-phenotype correlation

Conditions: Limbus Corneae

Summary: the study aims at searching for a genotype-phenotype correlation in patients with a genetic pathology of the ocular surface, in order to identify genetic abnormalities associated with the most severe clinical situations.


Eligibility criteria:
inclusion criteria: * genetic pathology of ocular surface exclusion criteria: * agonal glaucoma * low vision mostly related to retinal pathology * pregnant or breast feeding patient
brimonidine tartrate for the treatment of injection related erythema

Conditions: Relapsing-Remitting Multiple Sclerosis (RRMS)

Summary: the primary objective of this study is to evaluate the injection related erythema (ire) mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel (placebo). the secondary study objectives are to evaluate the ire mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel on a more stringent definition scale, in accordance with the primary endpoint of the original brimonidine pivotal trials and participants' satisfaction with the overall appearance of their skin.

participants naïve to treatment with subcutaneous (sc) interferons or oral disease modifying therapy (dmt) who are about to start plegridy pen therapy will be screened for participation in this phase iv trial. participants will remain on plegridy therapy as prescribed by their physician. plegridy will not be provided to participants by biogen as a part of this study.

Eligibility criteria:
key inclusion criteria: * rrms patients naïve to treatment with sc interferon or oral and/or iv dmt for which plegridy is deemed necessary by the treating physician. * patient willing and able to complete psa and paa questionnaires with minimal assistance. key exclusion criteria: * known allergy to any interferon or any component of peginterferon beta-1a. * patients with hypersensitivity to brimonidine topical gel. * patients with other skin disorders. * history of previous treatment with brimonidine tartrate. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: erythema plegridy injection site reaction (isr) ms rrms
efficacy of botulinum toxin in scleroderma-associated raynaud's syndrome

Conditions: Scleroderma; Raynaud's Syndrome

Summary: this is a randomized, double-blinded, clinical trial assessing the therapeutic efficacy of botulinum toxin a (onabotulinumtoxin a) in treating scleroderma-associated raynaud's syndrome. each patient will undergo injection with a treatment dose of botulinum toxin a in one randomly-selected hand, and the contralateral hand will be injected with sterile saline (placebo) to serve as a control. study participants at the first study visit will complete study questionnaires, their hands will be assessed clinically for digital ulceration, and their hands will undergo non-invasive laser doppler imaging to assess blood flow. after this initial assessment, the patients will undergo peri-arterial injection of botulinum toxin a in one hand, and of sterile saline solution (placebo) in the other, in a randomized, blinded manner. patient will report the severity of their raynaud's symptoms weekly over the four month study period. at one month post-injection, the patient will complete study questionnaires, their hands will be assessed clinically for digital ulceration, and their hands will undergo non-invasive laser doppler imaging. at four months post-injection, the patient will again complete study questionnaires, their hands will be assessed clinically for digital ulceration, and their hands will undergo non-invasive laser doppler imaging. in addition, patient will be given the option of one week post-injection visit, at which point the same assessment will be performed. at the conclusion of the study, unblinding will occur.


Eligibility criteria:
inclusion criteria: * aged 18 years and older * diagnosed with scleroderma. * symptoms of raynaud's syndrome affecting both hands (not necessarily to equal extents) * ability to return/be available for follow-up evaluations * able and willing to give informed consent * able to speak and read in the english language. exclusion criteria: * a history of myasthenia gravis. * reported allergy or hypersensitivity to any botulinum toxin preparation. * active infection in either hand. * patients who have ever received botulinum toxin vaccine. * pregnant or lactating women. * females unable or unwilling to maintain abstinence or use contraception for 28 days following the injections. * patients who have previously undergone any vascular surgery on the upper extremity, including surgical sympathectomies. * current use of any aminoglycoside antibiotic

Keywords: scleroderma, systemic raynaud disease botulinum toxins, type a
comparison of gray-scale inverted rib series with conventional ones in rib fracture detection by emergency physicians and medical students

Conditions: Rib Fracture

Summary: there were many studies which examined the availability of inverted gray-scale chest x-ray for increasing the detection of lung nodules. in emergency medicine, rib fracture is an important part for patient's disposition, so investigators designed this study to evaluate the availability of inverted gray-scale chest x-ray for the detection of rib fracture.


Eligibility criteria:
inclusion criteria: * emergency resident who want to participate exclusion criteria: * emergency resident who does not want to participate

Keywords: rib fracture inverted grayscale
safety of enc-201-ced encrt

Conditions: Diabetes Mellitus, Type 1

Summary: the purpose of the study is to evaluate the safety and tolerability of enc-201-ced in a subcutaneous space in patients with type i diabetes.


Eligibility criteria:
inclusion criteria: * candidates must satisfy site's eligibility for standard of care islet infusion. exclusion criteria: * candidates are excluded based on the site's criteria for standard of care islet infusion.

Keywords: diabetes mellitus diabetes mellitus, type 1 glucose metabolism islet infusion pancreas transplant
topical ascorbic acid for treatment of squamous cell skin cancer

Conditions: Squamous Cell Cancer; Squamous Cell Carcinoma; Skin Cancer; Non-melanoma Skin Cancer

Summary: randomized comparative trial of a 30% solution of ascorbic acid in 95% dimethylsulfoxide applied topically twice a day for 8 weeks vs 5% imiquimod cream in the treatment of biopsy proven squamous cell carcinomas of the skin in otherwise healthy adult patients. outcome measure was biopsy proven resolution of the carcinoma.

importance: skin cancer is the most common cancer in the united states, with more people diagnosed each year than all other cancers combined. basal cell and squamous cell cancers are the most common forms with an estimated 6-7 million cases diagnosed annually. costs of treating these cancers in the u.s. are estimated at $9-10 billion annually. task force consensus guidelines suggest mohs surgery as the treatment of choice, and as the single most precise and effective treatment method. however, cost and issues of cosmesis are principal disadvantages. previous studies show the effectiveness of a topical solution of ascorbic acid in the treatment of bcc. this study extends previous work to evaluate efficacy in the treatment of scc of the skin. objective: to evaluate efficacy of a therapeutic regimen in treating squamous cell cancer, consisting of 30% ascorbic acid in 95% dimethylsulfoxide topically applied at home by patients twice a day for 8 weeks, vs 5% imiquimod cream which is an fda approved treatment for scc. design, setting, and participants: this study was carried out in accordance with principles of the declaration of helsinki. detailed informed consent was obtained from each patient. eligible participants of any age had histologically confirmed primary, previously untreated, nodular or superficial scc. patients with cancers larger than 2 cm or deeper than 2 mm were excluded from the study. imiquimod was applied once daily for 5 days per week as per manufacturer instructions for treatment of scc. patients were randomly assigned to treatment group. participants and outcome assessors were blinded to treatment protocol. patients were seen at initial visit, 4 weeks, 8 weeks, and six weeks after treatment conclusion for final biopsy. the aa treatment was a solution while the imq a cream, however participants were simply told they would be receiving a topical treatment with instructions on how to apply, thus the blinding was intact. main outcomes and measures number of lesions out that were cancer free after 8 wks of treatment.

Eligibility criteria:
inclusion criteria: presence of biopsy proven squamous cell cancer of the skin - exclusion criteria: previous history of malignancy, diabetes, immunocompromised -

Keywords: squamous cell cancer skin cancer non-melanoma skin cancer squamous cell carcinoma
neuropathic pain after breast surgery

Conditions: Chronic Neuropathic Pain, Postoperative; Chronic Pain, Postoperative; Chronic Chemotherapy-induced Neuropathic Pain; Chronic Chemotherapy-induced Pain; Chronic Chemotherapy-induced Peripheral Neuropathy

Summary: to understand pain pathophysiology in terms of risk factors and protective mechanisms ranging from molecular pathways to societal impacts.

pain and loss of function are intimately associated with the reaction of the nervous system to neural damage. a lesion to the somatosensory nervous system caused by mechanical trauma, metabolic disease, neurotoxic chemicals, infection or tumor invasion may give rise to neuropathic pain. neuropathic pain affects around 8% of the population and may negatively impact the individual's quality of life; moreover, the condition leads to significant costs to the healthcare system and society. not all subjects with such a lesion develop neuropathic pain, and those who do develop neuropathic pain have varying degrees of symptom severity, impact and outcomes and may respond unpredictably to treatment. the interaction between genetics and environmental and clinical factors in a susceptible individual most likely contribute to the variation in pain prevalence and severity. a better understanding of the exact nature of these risk factors and their interactions will ultimately improve the patients' health, both in terms of recognizing patients at risk and identifying new treatment modalities. genetic, neurophysiological and psychological factors all influence the risk of developing persistent pain. it is therefore possible to describe a genetic, neurophysiological and psychological profile, in particular in patients experiencing neuropathic pain after surgery and/or neurotoxic chemotherapy.

Eligibility criteria:
inclusion criteria: * patients scheduled for breast cancer resection performed via lumpectomy (partial or segmental mastectomy) or mastectomy with or without sentinel lymph node biopsy and axillary lymph node dissection, and any combinations hereof. * willingness and ability to comply with study procedures as judged by the site investigator/manager. * expected availability for follow-up throughout the study, i.e., \~12 months. * willingness to voluntarily sign and date the study-specific informed consent form. exclusion criteria: * mental incapacity or language barriers precluding adequate understanding of study procedures. * current alcohol or substance abuse according to the site investigator's medical judgement. * unsuitability for participation in the study for any other reason, e.g. due to a significant serious underlying condition (e.g. other cancer or aids), as determined by the site investigator/manager.
trc105 combined with standard-dose bevacizumab for two patients with metastatic and refractory choriocarcinoma

Conditions: Choriocarcinoma

Summary: the purpose of this study is to determine whether trc105 in combination with bevacizumab is effective in the treatment of two patients with metastatic and refractory choriocarcinoma.

bevacizumab is a monoclonal antibody to vascular endothelial growth factor (vegf) that inhibits angiogenesis and extends survival in patients with a wide variety of solid tumor types. trc105 is a monoclonal antibody to cd105, an angiogenic target highly expressed on the tumor vessels and the tumor cells in choriocarcinoma. together, these antibodies may be efficacious in metastatic and refractory choriocarcinoma, a tumor type that is highly vascular and expresses endoglin. the purpose of this study is to determine whether trc105 in combination with bevacizumab is effective in the treatment of two patients with metastatic and refractory choriocarcinoma.

Eligibility criteria:
inclusion criteria: 1. willingness and ability to consent for self to participate in study 2. willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures 3. measurable disease by recist 1.1 and elevated serum β-hcg 4. histologically proven choriocarcinoma that has progressed despite all described lines of chemotherapy for this condition exclusion criteria: 1. prior treatment with trc105 2. serious dose-limiting toxicity related to prior bevacizumab 3. current treatment on another therapeutic clinical trial 4. uncontrolled chronic hypertension defined as systolic \> 140 or diastolic \> 90 despite optimal therapy (initiation or adjustment of bp medication prior to study entry is allowed provided that the average of 3 bp readings at a visit prior to enrollment is \< 140/90 mm hg) 5. symptomatic pericardial or pleural effusions 6. uncontrolled peritoneal effusions requiring paracentesis more frequently than every 2 weeks 7. active bleeding or pathologic condition that carries a high risk of bleeding (i.e. hereditary hemorrhagic telangiectasia) 8. thrombolytic or anticoagulant use (except to maintain i.v. catheters) within 10 days prior to first day of study therapy 9. cardiac dysrhythmias of nci ctcae grade ≥ 2 within the last 28 days 10. known active viral or nonviral hepatitis 11. open wounds or unhealed fractures within 28 days of starting study treatment 12. history of peptic ulcer disease or erosive gastritis within the past 6 months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (egd) within 28 days of starting study treatment 13. known human immunodeficiency virus (hiv) or acquired immunodeficiency syndrome (aids) related illness 14. other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for this study
acute effects of sitting and physical activity on brain health

Conditions: Healthy Adults

Summary: the specific aim of this study is to understand how a working day composed of prolonged sitting, sitting regularly interrupted by light aerobic exercise or resistance exercise affects an important mechanism underpinning healthy brain functions, namely cerebral blood flow. it is primarily focused on investigating these effects in ecologically valid conditions, i.e. activity patterns that closely resemble a typical day at the office.

the study will be a controlled crossover experimental trial with three conditions involving 13 adult participants aged between 40 and 60 years. each participant will complete each of the three experimental conditions, separated by a washout period of minimum four days. as well, physical activity behaviours and sleep the day/night before the test day will be measured. the first visit will be a familiarization session. on the second, third, and fourth visits, participants will undergo three different standardized 3-hour interventions in a randomized order. before and immediately after the three-hour interventions, blood pressure, augmentation index, and cerebral hemodynamic response of the prefrontal cortex during standardized cognitive tasks (1,2, and 3-back tests) will be measured. additionally, saliva samples will be collected the morning of the test day and before and after the interventions, blood glucose will be assessed continuously during the trial, and fitness will be measured at the familiarization visit.

Eligibility criteria:
inclusion criteria: - has a bmi under 35kg/m2 exclusion criteria: * has diabetes, epilepsy, or circulatory conditions * has experienced heart failure, stroke, or myocardial infarction * takes treatment for high blood pressure, sleep disorders, depression, or psychosis
a multi-center randomized study to evaluate the efficacy and safety of an investigational lubricant eye drop

Conditions: Dry Eye

Summary: the efficacy, safety and acceptability of an investigational lubricant eye drop in subjects with dry eye will be evaluated in comparison with currently-available lubricant eye drops.


Eligibility criteria:
inclusion criteria: * mild, moderate, or severe dry eye symptoms and current eye drop use; * reduced tear stability or tear production exclusion criteria: * none
an evaluation of brief online hypnosis for migraine and tension-type headaches

Conditions: Migraine; Tension-Type Headache

Summary: this study aims to conduct an initial evaluation of whether a single, online, group-based session of hypnosis followed by self-hypnosis can decrease symptoms of migraine and tension-type headaches as well as improve quality of life and perceived self-efficacy over the condition.

this study is a pilot randomised controlled trial (rct) comparing a single, online, group-based session of hypnosis followed by self-hypnosis for people with migraines or tension-type headaches with a wait-list control. a battery of self-report measures and a 2-week headache diary will be administered online at baseline (weeks 0 and 1), post-intervention (weeks 7 and 8) and at follow-up (weeks 11 and 12).

Eligibility criteria:
inclusion criteria: * self-reported diagnosis of migraine or tension-type headaches from a general practitioner (i.e. family physician) and/or specialist physician. * score above the cut-off for either migraine or tension-type headache on the headache screening questionnaire. * have experienced at least one headache every two weeks over the last 3 months. * otherwise healthy physically and mentally. * able to understand written and spoken english. * have the it equipment necessary to access zoom videoconferencing and the qualtrics survey system. exclusion criteria: * substantial medical or psychiatric co-morbidities including diagnoses of epilepsy, psychosis or personality disorder, and/or taking psychiatric medication. * a diagnosis of medication overuse headache.
real world evidence of xen45 gel implant in pseudoexfoliation glaucoma

Conditions: Pseudoexfoliation Syndrome; Pseudoexfoliation Glaucoma in Both Eyes; Open Angle Glaucoma

Summary: the xen implant is an ab interno device that has been shown to be effective in reducing intraocular pressure in several types of glaucoma, although the evidence in pseudoexfoliative glaucoma is limited. the present retrospective observational study aims to increase knowledge about the long-term effectiveness and safety of the implant in pseudoexfoliative glaucoma. researchers will compare the results with data from patients with open-angle glaucoma.


Eligibility criteria:
inclusion criteria: data will be collected for all patients with pseudoexfoliation glaucoma (pxfg), ocular hypertension (oht) and pseudoexfoliation syndrome, poag and other secondary open angle glaucoma (oag) diagnosed, who underwent surgery from 2018 to 2022. patients should be candidates for filtering glaucoma surgery for the following indications: * uncontrolled intraocular pressure (iop) * intolerance or non-adherence to topical treatment * glaucoma progression despite topical therapy * surgical cataract patients undergoing phacoemulsification, who were treated with two or more hypotensive drugs and wished to withdraw the medication due to side effects and/or discomfort of the treatment. refractory glaucoma and eyes with previous filtering surgery, previous laser treatments or micropulse transscleral cyclophotocoagulation will be also included. exclusion criteria: * patients with follow up less than 12 months. * patients with end-stage glaucoma, uveitic and angle closure glaucoma.

Keywords: xen
sof plus dcv in treating chinese treatment-experienced hcv patients

Conditions: Chronic Hepatitis C Infection

Summary: for those chronic hepatitis c patients, who are interferon-ineligible or intolerant, there is a burning need for the development of pan-oral interferon-free regimen. the investigators examine the efficacy and safety of sofosbuvir, a ns5b nucleotide polymerase inhibitor and daclatasvir, an ns5a replication complex inhibitor in chinese treatment-experienced cirrhosis patients with chronic g1b infection.

chinese genotype 1b hcv treatment-experienced cirrhotic patients are recruited and treated with 12 weeks sofosbuvir 400 mg daily plus daclatasvir 60 mg daily. at baseline, liver stiffness measurement (lsm) using transient elastography (fibroscan®) is used to assess liver fibrosis and the single nucleotide polymorphism ofinterferon-λ 3 (il-28, rs12979860, c or t) and ifln4 (ss469415590, tt or δg) is determined. serial measurement of plasma hcv rna levels are performed with the use of the cobas taqman real-time assay (roche version 2.0), at baseline, day 2,4 and 7, week 2,4 and 12, post-treatment week 12. the primary efficacy end point is a sustained virologic response 12 weeks after the end of treatment (svr12).

Eligibility criteria:
inclusion criteria: 1. patients chronically infected with hcv genotype-1b; 2. documented evidence of relapse after completion of previous course of interferon-based regimen with or without ribavirin; 3. hcv rna level greater than 10,000 iu/ml at screening; 4. patients with compensated cirrhosis are permitted. exclusion criteria: 1. current or prior history: clinically-significant illness (other than hcv) or any other major medical disorder that may interfere with treatment, assessment or compliance with the protocol; individuals currently under evaluation for a potentially clinically-significant illness (other than hcv) are also excluded; 2. screening ecg with clinically significant abnormalities; 3. laboratory results outside of acceptable ranges at screening; 4. infection with hepatitis b virus (hbv) or human immunodeficiency virus (hiv).